2PVW

A high resolution structure of human glutamate carboxypeptidase II (GCPII) in complex with 2-(phosphonomethyl)pentanedioic acid (2-PMPA)

2PVW の概要

• エントリーDOI: 10.2210/pdb2pvw/pdb
• 分子名称: Glutamate carboxypeptidase 2, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (9 entities in total)
• 機能のキーワード: prostate specific membrane antigen; metallopeptidase; folate hydrolase; glutamate carboxypeptidase ii; naaladase; 2-(phosphonomethyl)pentanedioic acid; 2-(pmpa), hydrolase
• 由来する生物種: Homo sapiens (human)
• 細胞内の位置: Cell membrane; Single-pass type II membrane protein. Isoform PSMA': Cytoplasm: Q04609
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 82977.01

構造登録者

Barinka, C.,Lubkowski, J. (登録日: 2007-05-10, 公開日: 2007-05-22, 最終更新日: 2024-11-06)

主引用文献

Barinka, C.,Rovenska, M.,Mlcochova, P.,Hlouchova, K.,Plechanovova, A.,Majer, P.,Tsukamoto, T.,Slusher, B.S.,Konvalinka, J.,Lubkowski, J.
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
J.Med.Chem., 50:3267-3273, 2007

PubMed Abstract: Inhibition of glutamate carboxypeptidase II (GCPII) has been shown to be neuroprotective in multiple preclinical models in which dysregulated glutamatergic transmission is implicated. Herein, we report crystal structures of the human GCPII complexed with three glutamate mimetics/derivatives, 2-(phosphonomethyl)pentanedioic acid (2-PMPA), quisqualic acid (QA), and L-serine O-sulfate (L-SOS), at 1.72, 1.62, and 2.10 A resolution, respectively. Despite the structural differences between the distal parts of the inhibitors, all three compounds share similar binding modes in the pharmacophore (i.e., S1') pocket of GCPII, where they are stabilized by a combination of polar and van der Waals interactions. The structural diversity of the distal parts of the inhibitors leads to rearrangements of the S1' site that are necessary for efficient interactions between the enzyme and an inhibitor. The set of structures presented here, in conjunction with the available biochemical data, illustrates a flexibility of the GCPII pharmacophore pocket and highlights the structural features required for potent GCPII inhibition. These findings could facilitate the rational structure-based drug design of new GCPII inhibitors in the future.

PubMed: 17567119
DOI: 10.1021/jm070133w

実験手法

X-RAY DIFFRACTION (1.71 Å)